What specific strategies are currently in the T2D pharmacologic toolkit that have been shown effective for reducing PPG? Where do GLP-1 RAs fit into this scheme?

What specific strategies are currently in the T2D pharmacologic toolkit that have been shown effective for reducing PPG? Where do GLP-1 RAs fit into this scheme?

What specific strategies are currently in the T2D pharmacologic toolkit that have been shown effective for reducing PPG? Where do GLP-1 RAs fit into this scheme?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Lawrence Leiter, MD, FRCP(C), FACP

Lawrence Leiter, MD, FRCP(C), FACP

Head, Division of Endocrinology and Metabolism Director, Lipid Clinic Associate Director, Clinical Nutrition and Risk Factor Modification Centre St. Michael’s Hospital Professor of Medicine and Nutritional Sciences University of Toronto Toronto, Ontario